Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
NEJM study shows strong protection across strains
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Subscribe To Our Newsletter & Stay Updated
